37465-61-5 Usage
Uses
Used in Pharmaceutical Industry:
2-[2-(1H-Indol-3-yl)-ethylamino]-ethanol is used as an intermediate compound for the synthesis of various pharmaceuticals, due to its ability to act as a neurotransmitter or neuromodulator in the central nervous system.
Used in Psychoactive Substances:
2-[2-(1H-Indol-3-yl)-ethylamino]-ethanol is used as a precursor in the production of certain psychoactive substances, given its presence in the human body and its role in biochemical processes.
Used in Research Applications:
2-[2-(1H-Indol-3-yl)-ethylamino]-ethanol is used as a research chemical for studying the effects of neurotransmitters and neuromodulators on the central nervous system, as well as for investigating its potential therapeutic applications in various neurological disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 37465-61-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,4,6 and 5 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 37465-61:
(7*3)+(6*7)+(5*4)+(4*6)+(3*5)+(2*6)+(1*1)=135
135 % 10 = 5
So 37465-61-5 is a valid CAS Registry Number.
InChI:InChI=1/C12H16N2O/c15-8-7-13-6-5-10-9-14-12-4-2-1-3-11(10)12/h1-4,9,13-15H,5-8H2
37465-61-5Relevant academic research and scientific papers
PEPTIDYLARGININE DEIMINASES (PAD) INHIBITORS
-
Page/Page column 85-86, (2014/12/12)
The present invention relates to compounds of the formula (I): as inhibitors of peptidylarginine deiminases (PADs). It also concerns their use in therapy, particularly in the prophylaxis or treatment of neural injury, and other conditions including cancer, multiple sclerosis, glaucoma, arthritis, rheumatoid arthritis lupus, Alzheimer's disease, and ulcerative colitis.
Novel indolo [3,2,1-de] [1,4] oxazino [2,3,4-ij] [1,5]
-
, (2008/06/13)
Novel compounds selected from the group consisting of all possible racemic or optically active forms of compounds of the formula STR1 wherein R1 and R2 are individually selected from the group consisting of hydrogen, alkyl and alkoxy of 1 to 5 carbon atoms, -OH, -CF3 and -NO2 and STR2 is selected from the group consisting of STR3 and their non-toxic, pharmaceutically acceptable acid addition salts having a very good analgesic activity as well as antidepressive, neuronal protective, anti-anoxic, anti-ischemic and no-otropic activities.
